Hansa Biopharma AB (publ) (HNSBF)
USD 2.83
(0.0%)
USD 2.83
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -831.72 Million SEK | -36.09% |
| 2022 | -611.13 Million SEK | -11.46% |
| 2021 | -548.28 Million SEK | -30.28% |
| 2020 | -420.85 Million SEK | -16.9% |
| 2019 | -360 Million SEK | -45.18% |
| 2018 | -247.97 Million SEK | -40.37% |
| 2017 | -176.66 Million SEK | -58.97% |
| 2016 | -111.12 Million SEK | -67.7% |
| 2015 | -66.26 Million SEK | -128.17% |
| 2014 | -29.04 Million SEK | -65.37% |
| 2013 | -17.56 Million SEK | -6.66% |
| 2012 | -16.46 Million SEK | 32.99% |
| 2011 | -24.57 Million SEK | -30.4% |
| 2010 | -18.84 Million SEK | -19.17% |
| 2009 | -15.81 Million SEK | -518.1% |
| 2008 | -2.55 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -218.57 Million SEK | -75.62% |
| 2024 Q3 | -103.79 Million SEK | 50.08% |
| 2024 Q2 | -207.94 Million SEK | 4.87% |
| 2023 Q3 | -250.65 Million SEK | 0.21% |
| 2023 Q4 | -124.45 Million SEK | 50.35% |
| 2023 FY | -831.72 Million SEK | -36.09% |
| 2023 Q1 | -205.42 Million SEK | -38.17% |
| 2023 Q2 | -251.18 Million SEK | -22.28% |
| 2022 FY | -611.13 Million SEK | -11.46% |
| 2022 Q2 | -170.07 Million SEK | -22.85% |
| 2022 Q3 | -153.95 Million SEK | 9.48% |
| 2022 Q4 | -148.67 Million SEK | 3.43% |
| 2022 Q1 | -138.43 Million SEK | 15.27% |
| 2021 FY | -548.28 Million SEK | -30.28% |
| 2021 Q4 | -163.39 Million SEK | -10.12% |
| 2021 Q3 | -148.37 Million SEK | -11.9% |
| 2021 Q2 | -132.59 Million SEK | -27.58% |
| 2021 Q1 | -103.92 Million SEK | 1.8% |
| 2020 Q1 | -93.36 Million SEK | 15.77% |
| 2020 FY | -420.85 Million SEK | -16.9% |
| 2020 Q3 | -122.4 Million SEK | -23.34% |
| 2020 Q2 | -99.24 Million SEK | -6.29% |
| 2020 Q4 | -105.83 Million SEK | 13.54% |
| 2019 Q4 | -110.85 Million SEK | -17.6% |
| 2019 FY | -360 Million SEK | -45.18% |
| 2019 Q1 | -72.47 Million SEK | 10.77% |
| 2019 Q2 | -82.41 Million SEK | -13.7% |
| 2019 Q3 | -94.26 Million SEK | -14.38% |
| 2018 Q3 | -61.45 Million SEK | -4.52% |
| 2018 Q1 | -46.49 Million SEK | 5.08% |
| 2018 Q2 | -58.79 Million SEK | -26.45% |
| 2018 FY | -247.97 Million SEK | -40.37% |
| 2018 Q4 | -81.22 Million SEK | -32.18% |
| 2017 Q3 | -37.52 Million SEK | 16.89% |
| 2017 Q4 | -48.98 Million SEK | -30.54% |
| 2017 FY | -176.66 Million SEK | -58.97% |
| 2017 Q1 | -44.99 Million SEK | -34.09% |
| 2017 Q2 | -45.15 Million SEK | -0.35% |
| 2016 Q2 | -30.67 Million SEK | -53.54% |
| 2016 Q4 | -33.55 Million SEK | -24.62% |
| 2016 FY | -111.12 Million SEK | -67.7% |
| 2016 Q3 | -26.92 Million SEK | 12.21% |
| 2016 Q1 | -19.97 Million SEK | -4.56% |
| 2015 FY | -66.26 Million SEK | -128.17% |
| 2015 Q4 | -19.1 Million SEK | -37.12% |
| 2015 Q3 | -13.93 Million SEK | 38.09% |
| 2015 Q2 | -22.5 Million SEK | -109.84% |
| 2015 Q1 | -10.72 Million SEK | 16.02% |
| 2014 Q2 | -4.84 Million SEK | 19.17% |
| 2014 Q4 | -12.77 Million SEK | -135.41% |
| 2014 Q1 | -5.99 Million SEK | -34.45% |
| 2014 FY | -29.04 Million SEK | -65.37% |
| 2014 Q3 | -5.42 Million SEK | -11.9% |
| 2013 FY | -17.56 Million SEK | -6.66% |
| 2013 Q2 | -4.31 Million SEK | 0.0% |
| 2013 Q3 | -4.46 Million SEK | -3.27% |
| 2013 Q4 | -4.46 Million SEK | 0.0% |
| 2012 FY | -16.46 Million SEK | 32.99% |
| 2011 FY | -24.57 Million SEK | -30.4% |
| 2010 FY | -18.84 Million SEK | -19.17% |
| 2009 FY | -15.81 Million SEK | -518.1% |
| 2008 FY | -2.55 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -1009.507% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -12547.597% |
| SQZ Biotechnologies Company | -79.46 Million USD | -946.663% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 1669.905% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 1376.958% |
| Mesoblast Limited | -87.95 Million USD | -845.609% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -45585.647% |
| Genus plc | 7.9 Million USD | 10628.101% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -7536.245% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -22316.915% |
| Marizyme, Inc. | -65.34 Million USD | -1172.776% |
| ContraFect Corporation | -65.15 Million USD | -1176.564% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -9304.342% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -16922.294% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -48047.13% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -28655.419% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -10219.514% |
| MultiCell Technologies, Inc. | -380.07 USD | -218833272.8% |
| Accustem Sciences Inc. | -3.74 Million USD | -22100.4% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -1508.992% |
| EV Biologics, Inc. | -1.26 Million USD | -65537.888% |
| Q BioMed Inc. | -2.05 Million USD | -40430.327% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -22180.204% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -131416.571% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -34833.449% |
| Biomind Labs Inc. | -1.21 Million USD | -68392.711% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -7785.097% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -10423.981% |
| Skye Bioscience, Inc. | -37.64 Million USD | -2109.39% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -38231.396% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -5553585.897% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -11810.92% |
| IMV Inc. | -36.48 Million USD | -2179.578% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -5140.355% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -14197.47% |
| GB Sciences, Inc. | -1.36 Million USD | -60980.565% |
| Alpha Cognition Inc. | -13.77 Million USD | -5938.961% |
| HST Global, Inc. | -146.21 Thousand USD | -568753.02% |
| CSL Limited | 2.64 Billion USD | 131.481% |
| Halberd Corporation | -79.67 Thousand USD | -1043777.705% |
| Enzolytics Inc. | -2.17 Million USD | -38107.818% |
| Resverlogix Corp. | -3.61 Million USD | -22939.335% |
| Affymax, Inc. | -14.42 Million USD | -5666.223% |
| SYBLEU INC | -180.3 Thousand USD | -461187.603% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -26125.344% |
| argenx SE | -295.05 Million USD | -181.888% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -1228.647% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 848793.878% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -20834.343% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -27384.564% |
| AVAX Technologies, Inc. | -6.41 Million USD | -12867.971% |
| Zenith Capital Corp. | -10.59 Million USD | -7749.377% |
| Genscript Biotech Corporation | -95.47 Million USD | -771.121% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -3578421.642% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -19961.091% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -1375994.649% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -1292.573% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -26714.385% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -78657.113% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -42568.741% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -21678.476% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -41379.915% |
| BioStem Technologies, Inc. | -8.48 Million USD | -9704.569% |
| ONE Bio Corp. | 8.67 Million USD | 9685.769% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -188340.964% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -62181.016% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -47297.638% |
| Agentix Corp. | -1.37 Million USD | -60423.457% |
| LadRx Corporation | 400.44 Thousand USD | 207799.972% |
| Cell Source, Inc. | -5.32 Million USD | -15530.274% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -200083.403% |
| Regen BioPharma, Inc. | 1.02 Million USD | 81361.7% |
| Regen BioPharma, Inc. | 1.02 Million USD | 81361.7% |
| NovAccess Global Inc. | -4.76 Million USD | -17339.45% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 12111.101% |
| Itoco Inc. | -1.86 Million USD | -44400.922% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -18621.743% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -49733.433% |
| Kadimastem Ltd | -3.3 Million USD | -25047.261% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -304111.381% |
| CytoDyn Inc. | -49.84 Million USD | -1568.747% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1052270.529% |
| Mobile Lads Corp. | -2.26 Million USD | -36648.241% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -364486.393% |
| Qrons Inc. | -789.34 Thousand USD | -105268.108% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -88237.162% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -39739.401% |
| Rebus Holdings, Inc. | -1.02 Million USD | -81441.176% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -51471.955% |
| International Stem Cell Corporation | -131 Thousand USD | -634800.763% |
| Bioxytran, Inc. | -4.28 Million USD | -19332.701% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -1532402.948% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -32771.099% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -1630.155% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -39243.425% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -106409.649% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -26153.788% |
| Neutra Corp. | -233.46 Thousand USD | -356150.402% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -3998.96% |
| PureTech Health plc | -65.69 Million USD | -1165.994% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -3810.933% |
| IXICO plc | -1.17 Million USD | -70504.414% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -8278.362% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -1355.889% |
| CSL Limited | 2.64 Billion USD | 131.481% |
| Cellectis S.A. | -103.17 Million USD | -706.134% |